PLANT BIOREACTOR PROGRESS. By 2009 9 products were on the market, and 19 in clinical trials. By 2013 the commercial pace had accelerated after “the DARPA initiative challenged … companies to develop strategies for the large-scale manufacture of influenza vaccines, resulting in a successful Phase I clinical trial; in Europe the Pharma-Planta academic consortium gained regulatory approval for a plant-derived monoclonal antibody.”
http://lnkd.in/dUkpZGwhttp://lnkd.in/d33JGyV
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022